Cargando…
Tumorigenic de-differentiation: the alternative splicing way
The mechanism of acquisition of tumorigenic properties by somatic cells at the onset of cancer and later during relapse is a question of paramount importance in cancer biology. We have recently discovered a Muscleblind like-1 (MBNL1)-driven alternative-splicing mediated mechanism of tumorigenic de-d...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Taylor & Francis
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7671003/ https://www.ncbi.nlm.nih.gov/pubmed/33235913 http://dx.doi.org/10.1080/23723556.2020.1809959 |
| _version_ | 1783610850427273216 |
|---|---|
| author | Ray, Debleena Epstein, David M. |
| author_facet | Ray, Debleena Epstein, David M. |
| author_sort | Ray, Debleena |
| collection | PubMed |
| description | The mechanism of acquisition of tumorigenic properties by somatic cells at the onset of cancer and later during relapse is a question of paramount importance in cancer biology. We have recently discovered a Muscleblind like-1 (MBNL1)-driven alternative-splicing mediated mechanism of tumorigenic de-differentiation that is associated with poor prognosis, relapse and metastasis in common cancer types. |
| format | Online Article Text |
| id | pubmed-7671003 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Taylor & Francis |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-76710032020-11-23 Tumorigenic de-differentiation: the alternative splicing way Ray, Debleena Epstein, David M. Mol Cell Oncol Author’s Views The mechanism of acquisition of tumorigenic properties by somatic cells at the onset of cancer and later during relapse is a question of paramount importance in cancer biology. We have recently discovered a Muscleblind like-1 (MBNL1)-driven alternative-splicing mediated mechanism of tumorigenic de-differentiation that is associated with poor prognosis, relapse and metastasis in common cancer types. Taylor & Francis 2020-09-09 /pmc/articles/PMC7671003/ /pubmed/33235913 http://dx.doi.org/10.1080/23723556.2020.1809959 Text en © 2020 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. |
| spellingShingle | Author’s Views Ray, Debleena Epstein, David M. Tumorigenic de-differentiation: the alternative splicing way |
| title | Tumorigenic de-differentiation: the alternative splicing way |
| title_full | Tumorigenic de-differentiation: the alternative splicing way |
| title_fullStr | Tumorigenic de-differentiation: the alternative splicing way |
| title_full_unstemmed | Tumorigenic de-differentiation: the alternative splicing way |
| title_short | Tumorigenic de-differentiation: the alternative splicing way |
| title_sort | tumorigenic de-differentiation: the alternative splicing way |
| topic | Author’s Views |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7671003/ https://www.ncbi.nlm.nih.gov/pubmed/33235913 http://dx.doi.org/10.1080/23723556.2020.1809959 |
| work_keys_str_mv | AT raydebleena tumorigenicdedifferentiationthealternativesplicingway AT epsteindavidm tumorigenicdedifferentiationthealternativesplicingway |